CC BY
19
Abstracts. PHYTOPHARM 2017
THE METABOLOMIC APPROACH TO THE INVESTIGATION OF SECONDARY METABOLITES OF HERBAL SAMPLES
© Abramovich R.A., Vasil'ev V.G., Goryainov S.V., Potanina O.G., Ossipov V.I.
RUDN University, Shared Research and Educational Center, Moscow, Russian Federation
Metabolomics is a technology that includes a set of analytical and bioinformational methods for identifying and quantifying the aggregate of metabolites (metabolom) with low molecular weight in a cell, tissue or organism. The purpose of metabolomics is to determine changes in the biochemical phenotype of plants and to understand the functional significance of these changes (genetic changes, the influence of various environmental factors, etc.).
Analysis of plant metabolite is a complex task because of the wide range of differences in the physico-chemical properties of the analyzed compounds (molecular weights from 50 to 1500 Da, polarity, volatility, thermolability) and detectable concentrations [1].
The main methods for studying plant metabolomics are high-performance liquid or gas chromatography with mass spectrometric detection and NMR spectroscopy. The use of methods of multivariate statistical analysis makes it possible to visualize differences in the metabolom of the compared groups of plants.
Within the framework of the current cooperation agreement between the University of Turku (Finland) and RUDN University, the phenolic compounds of various medicinal plant raw materials (Lycopus europaeus, Tanacetum vulgare, Silybum marianum, Arctium lappa, Panax ginseng, Urtica dioica L., Aesculus hippocastanum, Hypericum perforatum, Cladonia stellaris) have been studied by high performance liquid chromatography with mass spectrometric detection. For each of the above plant species, their metabolic profiling has been carried out.
This publication was supported by the Ministry of Education and Science of the Russian Federation (the Agreement number 02.A03.21.0008).
References:
1. Weckwerth W, Fiehn O, 2002. Current Opinion in Biotechnology. 13:156-160.
INTESTINAL PERMEABILITY INDUCED BY PSYCHOLOGICAL STRESS: ACTION OF A HERBAL COMBINATION, STW 5
© Aubert Philippe1, Chevalier Julien1, Durand Tony1, Bessard Anne1, Kelber Olaf2, Abdel-Aziz Heba3, Neunlist Michel1
11nserm U1235-Institut des Maladies de l'Appareil Digestif du CHU de Nantes, Nantes, France;
2 Innovation and Development, Phytomedicines Supply and Development Center, Bayer Consumer; Health Division, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany;
3 Medical and Clinical Affairs Phytomedicines, Innovation and Development, Phytomedicines Supply and Development Center, Bayer Consumer Health Division, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
In the etiology of functional intestinal diseases, an enhanced paracellular and transcellular permeability is key. Therefore it is the question, whether herbal treatment options in these diseases can modulate permeability.
On the example of such a treatment option, STW 5, we did study the ability to modulate intestinal permeability under basal and repeated acute stress conditions.
Mice were treated for 14 days with STW 5 (3 mL/kg). After 10 days therapy, mice were subjected to water avoidance stress (WAS) during 4 consecutive days. In vivo permeability to FITC - Sulfonic Acid (FSA) and Horse Radish Peroxydase (HRP), total transit time and colonic transit (fecal pellet output - FPO) were assessed at day 0, day 10 and day 14 of IBS treatment. Ex vivo permeability to FSA and HRP was assessed on jejunum,
ileum, proximal and distal colon at day 14 using Ussing chambers. Corticosterone blood level was measured at day 11 and day 14.
STW 5 prevented the increase in permeability to FSA induced by WAS in the distal colon ex vivo. STW 5 prevented also the increase in permeability to HRP induced by WAS in the jejunum and proximal colon. In contrast, STW 5 did not influence the increase in colonic transit induced by WAS, and did not modify the change in corticosterone induced by WAS.
STW 5 obviously can prevent WAS induced changes in permeability in specific regions of the gastrointestinal tract. Such effects could contribute to the therapeutic effects e.g. in irritable bowel syndrome and support the use in patients in which barrier functions are altered.
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy]
vol. 15/2017/suppLement 1
